{
    "data": [
        {
            "id": "69a1b1fd24c37e0001bc0141",
            "title": "SVP Of Regal Rexnord Sold $64K In Stock",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">On February 26, a recent SEC filing unveiled that <strong>Alexander Scarpelli</strong>, SVP at <strong>Regal Rexnord</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/RRX\" target=\"_blank\">RRX</a>) made an insider sell.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>What Happened:</strong> A Form 4 filing from the <a href=\"https://www.sec.gov/Archives/edgar/data/0000082811/000008281126000075//Archives/edgar/data/82811/000008281126000075/0000082811-26-000075-index.htm\" target=\"_blank\">U.S. Securities and Exchange Commission</a> on Thursday showed that Scarpelli sold 290 shares of <strong>Regal Rexnord</strong>. The total transaction amounted to $64,887. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">In the Friday's morning session, <strong>Regal Rexnord</strong>'s shares are currently trading at $220.8, experiencing a down of 1.59%.</p><!--/$--><!--$--><h3 class=\"block core-block\">All You Need to Know About Regal Rexnord</h3><!--/$--><!--$--><p class=\"block core-block\">Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation &amp; Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Regal Rexnord: Delving into Financials</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Revenue Growth:</strong> Over the 3 months period, Regal Rexnord showcased positive performance, achieving a revenue growth rate of <strong>1.75%</strong> as of 31 December, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyzing Profitability Metrics:</strong></p><!--/$--><!--$--><ul class=\"block core-block\">\n<li>\n<p class=\"block core-block\"><strong>Gross Margin:</strong> The company shows a low gross margin of <strong>37.5%</strong>, suggesting potential challenges in cost control and profitability compared to its peers.</p>\n</li>\n<li>\n<p class=\"block core-block\"><strong>Earnings per Share (EPS):</strong> With an EPS below industry norms, Regal Rexnord exhibits below-average bottom-line performance with a current EPS of <strong>0.96</strong>.</p>\n</li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> Regal Rexnord's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.72</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Valuation Metrics:</strong></p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p><!--/$--><!--$--><h3 class=\"block core-block\">Why Insider Activity Matters in Finance</h3><!--/$--><!--$--><p class=\"block core-block\">Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.</p><!--/$--><!--$--><p class=\"block core-block\">While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.</p><!--/$--><!--$--><h3 class=\"block core-block\">The Insider's Guide to Important Transaction Codes</h3><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000082811\" target=\"_blank\"><strong>Check Out The Full List Of Regal Rexnord's Insider Trades.</strong></a></p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/insider_trade_3.jpg",
            "link": "https://www.benzinga.com/insights/news/26/02/50929306/svp-of-regal-rexnord-sold-64k-in-stock",
            "pub_date": "2026-02-27 23:02:24",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1b22124c37e0001bc0160",
            "title": "Here&#39;s How Much $100 Invested In First Solar 5 Years Ago Would Be Worth Today",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">First Solar (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/FSLR\" target=\"_blank\">FSLR</a>) has outperformed the market over the past 5 years by 6.35% on an annualized basis producing an average annual return of 18.4%. Currently, First Solar has a market capitalization of $20.78 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In FSLR:</strong> If an investor had bought $100 of FSLR stock 5 years ago, it would be worth <strong>$228.06</strong> today based on a price of $193.62 for FSLR at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">First Solar's Performance Over Last 5 Years</h3><!--/$--><!--$?--><template id=\"B:1\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/26/02/50929335/heres-how-much-100-invested-in-first-solar-5-years-ago-would-be-worth-today",
            "pub_date": "2026-02-27 23:03:01",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1afc324c37e0001bbff25",
            "title": "EXCLUSIVE: Can You Afford To Ignore It? High Roller CEO On Prediction Markets&#39; Multi-Billion-Dollar Surge",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Prediction markets aren't emerging — they're already <a href=\"https://www.benzinga.com/markets/prediction-markets/26/02/50905209/howard-marks-ai-is-multi-trillion-dollar-labor-replacement-but-prediction-markets-disagree\" target=\"_blank\">operating at scale</a>. And according to <strong>Seth Young</strong>, CEO of <strong>High Roller Technologies</strong> <strong>Inc</strong><a class=\"ticker-link\" data-exchange=\"AMEX\" data-ticker=\"ROLR\" href=\"https://www.benzinga.com/quote/ROLR\" rel=\"noopener\" target=\"_blank\">(AMEX:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/ROLR\" target=\"_blank\">ROLR</a>)<!-- -->, that changes the conversation entirely.</p><!--/$--><!--$--><p class=\"block core-block\">In an exclusive email interview with Benzinga, Young made it clear: this is no longer a question of experimentation. It's a question of participation.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>      • High Roller Technologies stock is trending lower. <a href=\"https://www.benzinga.com/quote/ROLR\" rel=\"noreferrer noopener\" target=\"_blank\">Why are ROLR shares declining?</a></strong></p><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Multi-Billion-Dollar Activity Changes The Equation</strong></h2><!--/$--><!--$--><p class=\"block core-block\">\"We believe this is the right moment to enter the U.S. prediction markets space because the category has reached economic scale and consumer engagement is clearly accelerating,\" Young said.</p><!--/$--><!--$--><p class=\"block core-block\">He didn't hedge.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">\"When a space is already demonstrating multi-billion-dollar annual activity, the question shifts from whether to participate to whether you can afford to overlook it.\"</p><!--/$--><!--$--><p class=\"block core-block\">That framing signals urgency. Young sees structural growth, not a cyclical spike. He revealed the company has spent the past year preparing for scale.</p><!--/$--><!--$--><p class=\"block core-block\">\"This is about long-term structural growth,\" he said. \"We're entering with a clear strategy and strong conviction in where the market is headed.\"</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>‘Building With Scale In Mind’</strong></h2><!--/$--><!--$--><p class=\"block core-block\">Young views prediction markets as more than a revenue line. He calls it both a financial opportunity and a digital audience expansion strategy.</p><!--/$--><!--$--><p class=\"block core-block\">\"If the category develops the way we expect, it can become a meaningful contributor over time,\" he said.</p><!--/$--><!--$--><p class=\"block core-block\">Even before revenue ramps, growing engaged users in regulated markets strengthens the broader business.</p><!--/$--><!--$--><p class=\"block core-block\">\"We're building this with scale in mind,\" Young added, emphasizing that as audience grows, financial impact follows.</p><!--/$--><!--$--><p class=\"block core-block\">For High Roller, this isn't a side bet. It's infrastructure.</p><!--/$--><!--$--><p class=\"block core-block\">And the CEO's message to the market sounds simple: ignoring multi-billion-dollar momentum carries its own risk.</p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50928798\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/The-Growth-Of-Prediction-Markets.jpeg",
            "link": "https://www.benzinga.com/markets/prediction-markets/26/02/50928798/exclusive-can-you-afford-to-ignore-it-high-roller-ceo-on-prediction-markets-multi-billion-dollar-surge",
            "pub_date": "2026-02-27 22:52:54",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1ae3024c37e0001bbfdd2",
            "title": "If You Invested $100 In ProShares Ultra Silver Stock 5 Years Ago, You Would Have This Much Today",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">ProShares Ultra Silver (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AGQ\" target=\"_blank\">AGQ</a>) has outperformed the market over the past 5 years by 17.99% on an annualized basis producing an average annual return of 30.08%. Currently, ProShares Ultra Silver has a market capitalization of $3.01 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In AGQ:</strong> If an investor had bought $100 of AGQ stock 5 years ago, it would be worth <strong>$378.67</strong> today based on a price of $184.98 for AGQ at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">ProShares Ultra Silver's Performance Over Last 5 Years</h3><!--/$--><!--$?--><template id=\"B:1\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/26/02/50928481/if-you-invested-100-in-proshares-ultra-silver-stock-5-years-ago-you-would-have-this-much-today",
            "pub_date": "2026-02-27 22:46:12",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1ae5f24c37e0001bbfe09",
            "title": "ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>ANI Pharmaceuticals Inc.</strong> <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"ANIP\" href=\"https://www.benzinga.com/quote/ANIP\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/ANIP\" target=\"_blank\">ANIP</a>)<!-- --> shares are down early Friday following the company’s <a href=\"https://www.benzinga.com/pressreleases/26/02/g50922452/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-reaffir\" rel=\"noreferrer noopener\" target=\"_blank\">strong fourth-quarter report</a>.</p><!--/$--><!--$--><p class=\"block core-block\">ANI Pharmaceuticals reported adjusted earnings of $2.33 per share, up from $1.63 a year ago, beating the consensus of $2.00.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Total net revenues for the fourth quarter reached $247.1 million, marking a 29.6% increase compared to the same period last year. The sales surpassed the <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus estimate of $231.53 million</a>.</p><!--/$--><!--$--><p class=\"block core-block\">The Rare Disease segment, which includes products like Cortrophin Gel, saw a remarkable 50.8% growth, contributing $131.3 million to the overall revenue.</p><!--/$--><!--$--><p class=\"block core-block\">In addition, ANI reported a net income of $27.5 million for the fourth quarter, translating to $1.18 per diluted share, a significant turnaround from a net loss of $10.7 million in the prior year.</p><!--/$--><!--$--><p class=\"block core-block\">Adjusted EBITDA for the fourth quarter of 2025 was $65.4 million, an increase of 30.6% from the fourth quarter of 2024.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Expects Over $1 Billion In 2026 Sales</h2><!--/$--><!--$--><p class=\"block core-block\">“2025 was a year of significant growth for our Rare Disease and Generics businesses, which drove expansion to both our top-and bottom-line,” said <strong>Nikhil Lalwani,</strong> President and CEO of ANI. </p><!--/$--><!--$--><p class=\"block core-block\">Lalwani expects “significant multi-year growth” for Cortrophin Gel as the company expands into underpenetrated specialty indications and launches a dedicated organization for acute <a href=\"https://www.benzinga.com/general/health-care\" rel=\"noreferrer noopener\" target=\"_blank\">gouty arthritis flares</a>. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Guidance</h2><!--/$--><!--$--><p class=\"block core-block\">“With a proven track record, we expect to deliver more than $1 billion in revenue in 2026, with Rare Disease representing approximately 60% of total revenue,” Lalwani added.</p><!--/$--><!--$--><p class=\"block core-block\">For fiscal 2026, ANI expects sales between $1.055-$1.115 billion versus the <a href=\"https://www.benzinga.com/calendars/guidance\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $982.54 million</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The guidance includes Cortrophin Gel sales expectation of $540 million – $575 million, and ILUVIEN sales guidance of $78-$83 million.</p><!--/$--><!--$--><p class=\"block core-block\">ANI Pharmaceuticals sees fiscal 2026 adjusted earnings of $8.83-$9.34 per share compared to the consensus of $8.58, with adjusted EBITDA of $275 million – $290 million.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">The stock is currently trading 5.2% above its 20-day simple moving average (SMA) and 8.1% below its 100-day SMA, indicating some short-term strength but potential resistance in the longer term. Over the past 12 months, shares have increased by 20%, and they are currently positioned closer to their 52-week highs than lows.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 50.00, which is considered neutral territory, indicating a balanced market sentiment. Meanwhile, MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure on the stock.</p><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD indicates mixed momentum, reflecting uncertainty in the stock’s near-term direction.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $99.50</li>\n<li><strong>Key Support</strong>: $54.10</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Buy Rating with an <a href=\"https://www.benzinga.com/quote/NASDAQ:ANIP/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">average price target</a> of $95.50. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Guggenheim</strong>: Buy (Raises Target to $124.00) (Jan. 16)</li>\n<li><strong>Barclays</strong>: Initiated with Overweight (Target $100.00) (Dec. 9, 2025)</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>ANIP Price Action:</strong> ANI Pharmaceuticals shares were up 3.71% at $80.01 during premarket trading on Friday, according to <a href=\"https://pro.benzinga.com/dashboard\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50928527\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Oakville--On--Canada---August-15--2021-C.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50928527/ani-pharmaceuticals-turns-profit-rare-disease-sales-surge-50",
            "pub_date": "2026-02-27 22:46:59",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}